Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report

ACTA MEDICA INDONESIANA · Vol. 49 No. 2 (2017)

ISSN
2338-2732, 0125-9326
Terbit
2017-08-08
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with lower cure rates with the anti-TB therapy and higher risk of developing drug resistance. Some risk factors for this recurrence are smoking, poor treatment adherence, low economic status, and weak immune status. This study is aimed to identify whether the use of fixed-dose combination (FDC) anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation. Methods: the search was conducted on MEDLINE, ProQuest, EBSCO, ScienceDirect, and Cochrane according to clinical question. The studies were selected based on inclusion and exclusion criteria and led to five useful articles. The selected studies were critically appraised for their validity, importance, and applicability. Results: five cohort studies were found with comparable validity. Only 1 study has accurate relative risk (RR) with 3.97 (1.14 – 13.80) and number needed to harm of 18. Other four studies fulfilled the applicability criteria for our case. Conclusion: the use of FDC anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 162 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Suhendro SuhendroAfiliasi tidak diketahui2
Siti SetiatiAfiliasi tidak diketahui2
Iris RengganisAfiliasi tidak diketahui2
Ari Fahrial SyamAfiliasi tidak diketahui2
Achmad FauziAfiliasi tidak diketahui1
Nikko DarnindroAfiliasi tidak diketahui1
Ari F SyamAfiliasi tidak diketahui1
Eppy EppyAfiliasi tidak diketahui1
Leonard NainggolanAfiliasi tidak diketahui1
Gurmeet SinghAfiliasi tidak diketahui1
Rabbinu R PribadiAfiliasi tidak diketahui1
Dyah PurnamasariAfiliasi tidak diketahui1
Catarina BudyonoAfiliasi tidak diketahui1
Denita Biyanda UtamiAfiliasi tidak diketahui1
Sally A NasutionAfiliasi tidak diketahui1
Lugyanti SukrismanAfiliasi tidak diketahui1
Ika Prasetya WijayaAfiliasi tidak diketahui1
Irma Wahyuni AnwarAfiliasi tidak diketahui1
Agus Joko SusantoAfiliasi tidak diketahui1
Kuntjoro HarimurtiAfiliasi tidak diketahui1
Suriani AlimuddinAfiliasi tidak diketahui1
Teguh DartantoAfiliasi tidak diketahui1
Iwan AriawanAfiliasi tidak diketahui1
Bagus TakwinAfiliasi tidak diketahui1
Akmal TaherAfiliasi tidak diketahui1
Anindya Pradipta SusantoAfiliasi tidak diketahui1
Damar P SusilaradeyaAfiliasi tidak diketahui1
Imam Budidarmawan PrasodjoAfiliasi tidak diketahui1
Prasandhya Astagiri YusufAfiliasi tidak diketahui1
Pratiwi Pudjilestari SudarmonoAfiliasi tidak diketahui1
Budi WiwekoAfiliasi tidak diketahui1
Erni J NelwanAfiliasi tidak diketahui1
Hamzah ShatriAfiliasi tidak diketahui1
Khie ChenAfiliasi tidak diketahui1
July KumalawatiAfiliasi tidak diketahui1
Fadrian FadrianAfiliasi tidak diketahui1
Ceva W PitoyoAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report</dc:title>
	<dc:creator>Pramudita, Arvin</dc:creator>
	<dc:creator>Rumende, Cleopas M</dc:creator>
	<dc:creator>Findyartini, Ardi</dc:creator>
	<dc:subject xml:lang="en-US">tuberculosis</dc:subject>
	<dc:subject xml:lang="en-US">fixed-dose combination</dc:subject>
	<dc:subject xml:lang="en-US">recurrent</dc:subject>
	<dc:description xml:lang="en-US">Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with lower cure rates with the anti-TB therapy and higher risk of developing drug resistance. Some risk factors for this recurrence are smoking, poor treatment adherence, low economic status, and weak immune status. This study is aimed to identify whether the use of fixed-dose combination (FDC) anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation. Methods: the search was conducted on MEDLINE, ProQuest, EBSCO, ScienceDirect, and Cochrane according to clinical question. The studies were selected based on inclusion and exclusion criteria and led to five useful articles. The selected studies were critically appraised for their validity, importance, and applicability. Results: five cohort studies were found with comparable validity. Only 1 study has accurate relative risk (RR) with 3.97 (1.14 – 13.80) and number needed to harm of 18. Other four studies fulfilled the applicability criteria for our case. Conclusion: the use of FDC anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2017-08-08</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/327</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 49 No. 2 (2017): Acta Medica Indonesiana; 175</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/327/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2017 Acta Medica Indonesiana</dc:rights>
</oai_dc:dc>